Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205704 | 0.91 | HTR7 (0.62) | CYP2D6HTR7KCNH2DRD2HTR2A | |
| SCHEMBL4515279 | 0.87 | KDM4E (0.58) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3198767 | 0.85 | DRD2 (0.52) | HSD17B10CYP2D6HTR7KCNH2DRD2 | |
| SCHEMBL3187817 | 0.85 | HTR7 (0.63) | GAACYP2D6HTR7KCNH2DRD2 | |
| SCHEMBL6174497 | 0.83 | KDM4E (0.65) | KDM4EMEN1ALDH1A1GAAHPGD | |
| SCHEMBL3189302 | 0.83 | KCNH2 (0.51) | CYP2D6HTR7KCNH2DRD2 | |
| SCHEMBL936761 | 0.82 | DRD3 (0.48) | CYP2D6HTR7KCNH2DRD2HTR2A | |
| SCHEMBL3187228 | 0.81 | DRD2 (0.67) | CYP2D6HTR7KCNH2DRD2 | |
| SCHEMBL3187894 | 0.81 | KCNH2 (0.83) | HTR7KCNH2DRD2HTR2AHTR1A | |
| SCHEMBL3194787 | 0.80 | CYP2D6 (0.64) | CYP2D6HTR7KCNH2DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | claimed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | KDM4E 3299/4885MEN1 4547/4885ALDH1A1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.